VWF: von Willebrand factor
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet- surface receptor complex GPIb-IX-V.
- Drugs that act on it: 4
- Approved: 3
- In phases 1 to 3: 1
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on VWF, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Protein or peptide 1
- Other 2
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Takeda Pharmaceuticals USA250%
- Archemix Corp.125%
- Sanofi125%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Von willebrand factor human | Approved | Takeda Pharmaceuticals USA | Other | Exogenous proteinvon Willebrand factor exogenous protein | 32 |
| Caplacizumab | Approved | Sanofi | Antibody | Inhibitorvon Willebrand factor inhibitor | 3 |
| Vonicog alfa | Approved | Takeda Pharmaceuticals USA | Protein or peptide | Exogenous proteinvon Willebrand factor exogenous protein | 3 |
| Egaptivon pegol | Phase 2 | Archemix Corp. | Other | Inhibitorvon Willebrand factor inhibitor | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Von Willebrand disease 2
- 0.82
- Von Willebrand disease 3
- 0.80
- Von Willebrand disease 1
- 0.79
- Von Willebrand disease type 2B
- 0.71
- Hereditary von Willebrand disease
- 0.68
- Von Willebrand disease type 2A
- 0.67
- Von Willebrand disease type 2M
- 0.65
- Von Willebrand disease type 2N
- 0.65
- Cancer
- 0.62
- Platelet-type von Willebrand disease
- 0.61
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2021748, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P04275, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets